Allarity Therapeutics ALLR Stock
Allarity Therapeutics Price Chart
Allarity Therapeutics ALLR Financial and Trading Overview
| Allarity Therapeutics stock price | 1.32 USD |
| Previous Close | 1.43 USD |
| Open | 1.42 USD |
| Bid | 1.05 USD x 200 |
| Ask | 1.68 USD x 200 |
| Day's Range | 1.27 - 1.51 USD |
| 52 Week Range | 0.77 - 2.35 USD |
| Volume | 153.19K USD |
| Avg. Volume | 193.7K USD |
| Market Cap | 21.64M USD |
| Beta (5Y Monthly) | 0.523 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.25 USD |
ALLR Valuation Measures
| Enterprise Value | 23.32M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.4020618 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 62.72053 |
| Price/Book (mrq) | 2.635659 |
| Enterprise Value/Revenue | 67.602 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Allarity Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.523 |
| 52-Week Change | 29.52% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 2.35 USD |
| 52 Week Low | 0.77 USD |
| 50-Day Moving Average | 1.47 USD |
| 200-Day Moving Average | 1.3 USD |
ALLR Share Statistics
| Avg. Volume (3 month) | 193.7K USD |
| Avg. Daily Volume (10-Days) | 187.42K USD |
| Shares Outstanding | 15.91M |
| Float | 15.6M |
| Short Ratio | 0.64 |
| % Held by Insiders | 5.96% |
| % Held by Institutions | 5.97% |
| Shares Short | 175.24K |
| Short % of Float | 1.09% |
| Short % of Shares Outstanding | 1.09% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -10752.00000000000000000000000000000000% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.69% |
| Return on Equity (ttm) | -87.92% |
Income Statement
| Revenue (ttm) | 345K USD |
| Revenue Per Share (ttm) | 0.02 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 345K USD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -11249000 USD |
| Diluted EPS (ttm) | -0.7 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 19.81M USD |
| Total Cash Per Share (mrq) | 1.25 USD |
| Total Debt (mrq) | 21.5M USD |
| Total Debt/Equity (mrq) | 310.64 USD |
| Current Ratio (mrq) | 1.232 |
| Book Value Per Share (mrq) | 0.516 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16627000 USD |
| Levered Free Cash Flow (ttm) | -20963750 USD |
Profile of Allarity Therapeutics
| Country | United States |
| State | FL |
| City | Tarpon Springs |
| Address | 123 E. Tarpon Ave. |
| ZIP | 34689 |
| Phone | 401 426 4664 |
| Website | https://www.allarity.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 7 |
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
Q&A For Allarity Therapeutics Stock
What is a current ALLR stock price?
Allarity Therapeutics ALLR stock price today per share is 1.32 USD.
How to purchase Allarity Therapeutics stock?
You can buy ALLR shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Allarity Therapeutics?
The stock symbol or ticker of Allarity Therapeutics is ALLR.
Which industry does the Allarity Therapeutics company belong to?
The Allarity Therapeutics industry is Biotechnology.
How many shares does Allarity Therapeutics have in circulation?
The max supply of Allarity Therapeutics shares is 15.91M.
What is Allarity Therapeutics Price to Earnings Ratio (PE Ratio)?
Allarity Therapeutics PE Ratio is now.
What was Allarity Therapeutics earnings per share over the trailing 12 months (TTM)?
Allarity Therapeutics EPS is -0.7 USD over the trailing 12 months.
Which sector does the Allarity Therapeutics company belong to?
The Allarity Therapeutics sector is Healthcare.
Allarity Therapeutics ALLR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2310.38 USD — |
-1.07
|
— — | 2287.99 USD — | 2333.46 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}